Drugs and Dementia:
The most commonly used drug linked to dementia is diphenhydramine,
which is used in many popular products such as Benadryl, Nytol Sominex,
Theraflu, Triaminic Allergy, etc. It is also implicated in drugs containing
chlorpheniramine (Aller-Chlor); oxybutynin (Ditropan) and tolterodine (Detrol)
for overactive bladder; and tricyclic antidepressants, such as doxepin or
amitriptyline.1
Background Data:
Acetylcholine is a critical brain chemical involved in the
transmission of nerve impulse and is especially important for proper memory and
cognitive function. For example, Alzheimer's disease is associated with a severe reduction in acetylcholine levels due
to reduced activity of the enzyme that manufactures acetylcholine (choline
acetyltransferase).2
Given the link between low acetylcholine levels and poor
brain function, including dementia, previous studies have linked drugs to
reduced acetylcholine activity as well as mild cognitive impairment. These
drugs include the ones mentioned earlier.
While discontinuation of the drugs is thought to reverse the
mental deficit, there is evidence that anticholinergic drugs may produce
permanent changes leading to irreversible dementia.
These drugs are known to cause short-term drowsiness or
confusion, which is included in the prescribing information, but the long-term
effects these drugs have on mental function are generally not known by
physicians or the people taking them.3 4 5
Other drugs, like sedative
hypnotic drugs (sleeping pills) and antihistamines, have also been linked to an
increased risk of dementia. All of these drugs, both prescription and
over-the-counter, are used at an alarming rate by the elderly population,
putting them at significant risk for dementia.
New Data:
To evaluate whether cumulative anticholinergic use is
associated with a higher risk of incident dementia, researchers examined
medical records from 3,434 participants 65 years or older with no dementia at
study entry. Initial recruitment occurred from 1994 through 1996 and from 2000
through 2003 and data through September 30, 2012 were also included in these
analyses.6
Exposure to anticholinergic drugs was determined from
computerized pharmacy records. Cumulative exposure was updated as participants
were followed up over a 10-year period. About 20% of the population was found
to be using anticholinergic drugs.
During the evaluation period, 797 participants (23.2%)
developed dementia, with 637 of these (80%) developing Alzheimer’s disease. A
10-year cumulative dose-response relationship was observed for dementia and
Alzheimer’s. In other words, the higher the cumulative anticholinergic use, the
greater the risk of dementia. The highest risk threshold was taking the minimum
daily effective dose of one of the anticholinergic agents every day for 3
years.
Even at low dosage or recommended levels, chronic use of
these drugs should be avoided.
Based upon these results, the authors of the study propose
efforts to increase awareness among health care professionals and older adults
about the risk of the use of these drugs over time.
Bottom Line
The results from this study highlight the importance of
avoiding long-term use of such drugs, including diphenhydramine and
over-the-counter sleeping pills. What this research further establishes is that
the human brain can be adversely affected by minor pharmacological agents,
highlighting the importance of using natural approaches that not only address
the key issue (e.g., insomnia, allergies, etc.) but also have a positive effect on brain function. For example, the natural compound enzymatically
modified isoquercitrin (EMIQ) has demonstrated significant anti-allergy effects
and also has been shown to block the formation of beta-amyloid, a protein that
is linked to causing the brain damage in Alzheimer’s disease.
1.
|
↑
|
Basu,
Ranita, Hiroko Dodge, Gary P. Stoehr, and Mary Ganguli. “Sedative-hypnotic
use of diphenhydramine in a rural, older adult, community-based cohort:
effects on cognition.” The American journal of geriatric psychiatry 11, no. 2
(2003): 205-213.
|
2.
|
↑
|
Richter,
Judith A., Elaine K. Perry, and Bernard E. Tomlinson. “Acetylcholine and
choline levels in post-mortem human brain tissue: preliminary observations in
Alzheimer’s disease.” Life sciences 26, no. 20 (1980): 1683-1689.
|
3.
|
↑
|
Starr,
John M., and Lawrence J. Whalley. “Drug-induced dementia.” Drug safety 11,
no. 5 (1994): 310-317.
|
4.
|
↑
|
Ancelin,
Marie L., Sylvaine Artero, Florence Portet, Anne-Marie Dupuy, Jacques
Touchon, and Karen Ritchie. “Non-degenerative mild cognitive impairment in
elderly people and use of anticholinergic drugs: longitudinal cohort study.”
Bmj 332, no. 7539 (2006): 455-459.
|
5.
|
↑
|
Mintzer,
Jacobo, and Alistair Burns. “Anticholinergic side-effects of drugs in elderly
people.” Journal of the Royal Society of Medicine 93, no. 9 (2000): 457.
|
6.
|
↑
|
Gray,
Shelly L., Sascha Dublin, Onchee Yu, Rod Walker, Melissa Anderson, Rebecca A.
Hubbard, Paul K. Crane, and Eric B. Larson. “Benzodiazepine use and risk of
incident dementia or cognitive decline: prospective population based study.”
bmj 352 (2016): i90.
|
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.